Previous 10 | Next 10 |
Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, today announced the successful completion of the squeeze-out merger under Swiss law (the “Squeeze-Out Merger”) pursuant to which VectivBio Holding AG (“VectivBio”...
Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to announce the publication of its latest report, titled "Transformative Therapies for Pruritus Management." This comprehensive report delves into the critical issue of pruritus, or chronic itch, and it...
2023-11-27 10:34:03 ET More on Tharimmune, Inc. Financial information for Tharimmune, Inc. For further details see: Tharimmune stock rockets 46% on positive Phase 1 data for PBC drug
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in a fireside chat at the Piper Sandler 35 th Annual Healthcare Conference on Wednesday, November 29, 2023 at 9:00 a.m. ET at the Lotte New York Palace. A live webcast of Ironwood’s fireside chat will be accessible th...
2023-11-09 14:56:37 ET More on Ironwood Pharmaceuticals Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2023 Earnings Call Transcript Ironwood Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation Ironwood Pharmaceuticals: The Right Play Now Ironwood ...
2023-11-09 10:39:02 ET Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2023 Earnings Conference Call November 09, 2023 08:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Offi...
2023-11-09 07:03:18 ET More on Ironwood Pharmaceuticals Ironwood Pharmaceuticals: The Right Play Now Ironwood: Pipeline Progresses As FDA Approves LINZESS Ironwood Pharmaceuticals Q3 2023 Earnings Preview JMP starts Ironwood at market outperform, cites potent...
– LINZESS ® (Iinaclotide) EUTRx prescription demand growth increased 8% year-over-year; LINZESS U.S. net sales of $279 million, an increase of 7% year-over-year – – Reported positive final data from STARS Nutrition, a Phase II study of apraglutide in shor...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Ironwood Pharmaceuticals Inc. (IRWD) is expected to report $0.17 for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its second quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 8, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...